Navigation Links
Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Date:2/11/2008

t loss for the year ended December 31, 2007 was $59.4 million, or $2.12 per share, and for the year ended December 31, 2006, the net loss was $55.6 million, or $2.69 per share.

As of December 31, 2007, cash, cash equivalents and investments were $90.8 million compared to $54.5 million at September 30, 2007. Anesiva completed a public offering of 12.3 million shares of its common stock in December 2007. The net proceeds, after deducting underwriting discounts and offering expenses, were approximately $47.7 million. Common shares issued and outstanding totaled approximately 40.4 million at December 31, 2007.

2008 Outlook

With the $47.7 million in net proceeds from the December 2007 common stock offering and $90.8 million in cash, cash equivalents and investments as of December 31, 2007, the company has sufficient resources to fund anticipated expenses for all of 2008 and into 2009. Anesiva plans to update this guidance, including estimated 2008 operating expenses, going forward. The company also plans to provide projections related to Zingo sales in the second half of 2008
In 2008, Anesiva anticipates accomplishing the following milestones:

-- File a supplemental New Drug Application for Zingo in the first quarter

of 2008 to expand the label to include adults;

-- Continue manufacturing preparations to support commercial introduction

of Zingo in the second quarter of 2008;

-- Initiate a Phase 3 trial evaluating Adlea in bunionectomy surgeries,

expected to occur imminently;

-- Initiate a Phase 3 trial evaluating Adlea in total knee replacement

surgeries in the first half of 2008;

-- Initiate additional Phase 2 trials in 2008 evaluating Adlea in

osteoarthritis of the knee and in arthroscopic shoulder surgeries;

-- Report data from Phase 2 trial of Adlea in total knee replacement

surgeries and Phase 3 trial in bunionectomy surgeries;

In ad
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Anesiva Appoints Daniel Janney to Board of Directors
2. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
3. Anesiva Announces Completion of Common Stock Offering
4. Anesiva Raises $45 Million in Common Stock Offering
5. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
6. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Global biostimulants market is expected to reach $2,524.02 ... of 12.5%. In order to cater to the ... impacts, farmers are looking to adopt natural compounds ... effectively & efficiently. Biostimulants are consequently seen as ... investments. , Leading companies in the biostimulants market ...
(Date:11/26/2014)... and WILMINGTON, DE (PRWEB) November 26, 2014 ... Annual MPN Heroes recognition reception on December 5, 2014, ... Hematology’s annual meeting. The MPN Heroes event will honor ... in the field of myeloproliferative neoplasms (MPNs). , ... "Nashville," will discuss his family's cancer journey at the ...
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) ... to serve in a newly created position of ... Gavin will be responsible for managing the operations of ... business acquired in July 2014 and the recently acquired ... -based ProteinSimple develops and commercializes proprietary systems and ...
(Date:11/24/2014)... BUENA, N.J. , Nov. 24, 2014  IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... submissions in 2014 to seven, with eighteen submissions now ... Grenfell-Gardner , President and CEO of the Company, commented, ...
Breaking Biology Technology:2019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3IGI Laboratories, Inc. Announces ANDA Submission 2
... BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) today ... Life Sciences Conference in New York. A live ... 2007 at 2:00 p.m. Eastern,Time may be accessed ... will be archived for seven days. (Logo: ...
... September 24 ThalesNano Inc., a,leading developer ... and hydrogenation technology solutions, announced today that ... a subsidiary in the United,Kingdom and by ... Building its own subsidiary reflects ThalesNano,s ...
... (Nasdaq and MTAX: CTIC) today announced that Richard L. ... Chairman of the Board for,Systems Medicine, which was recently ... Genomics Institute ("TGen") in Arizona,uses the latest drug development ... and identify which drugs will be most effective,at treating ...
Cached Biology Technology:BioCryst to Present at UBS 2007 Global Life Sciences Conference 2BioCryst to Present at UBS 2007 Global Life Sciences Conference 3ThalesNano Inc. Opens Own Representation in the United Kingdom and has New Distribution Agreements for Europe and India 2Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI) 2Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI) 3
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/10/2014)... detergent pods began appearing on U.S. store shelves in ... numbers ever since. The small packets can be tossed ... out a liquid or powder. The convenience, though, has ... study from researchers at Nationwide Children,s Hospital found that ... reports of 17,230 children younger than 6 years of ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... 2010 Scientists studying the environmental impact of Hurricane ... city of New Orleans have revealed the ecological impact ... The findings, published in a special issue of ... caused significant ecological damage by altering coastal chemistry and ...
... exposure to ionizing radiation can result in mutations or ... Now a new study led by researchers with the ... Lab) has revealed another way in which radiation can ... cells, the researchers discovered that radiation exposure can alter ...
... invasive aquatic organism that is on the state,s most ... Bay and Coos Bay, and scientists say this "colonial ... economic and environmental implications. Its propensity to foul ... buoys could make it costly to control, and its ...
Cached Biology News:New research reveals Hurricane Katrina's impact on ecological and human health 2New research reveals Hurricane Katrina's impact on ecological and human health 3Study raises new concerns about radiation and breast cancer 2Study raises new concerns about radiation and breast cancer 3Invasive 'tunicate' appears in Oregon's coastal waters 2Invasive 'tunicate' appears in Oregon's coastal waters 3Invasive 'tunicate' appears in Oregon's coastal waters 4
... All serum is extensively scrutinized, ... criteria. All horses are ... and worming are controlled and ... lot consistency. Pricing: ...
... sets added in Dec 2005 , ... , Detection from as little as 25 ... primers available for hundreds of mammalian miRNAs ... RT-PCR , Ideal for validating expression ...
jub, ajuba homolog (Xenopus laevis)...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: